| 0 |
NECROBIOSIS LIPOIDICA DIABETICORUM |
1 |
0.0159 |
| 1 |
PRODUCT PRIMARY PACKAGING ISSUE |
1 |
0.0089 |
| 2 |
THERAPEUTIC PRODUCT EFFECTIVE FOR UNAPPROVED INDICATION |
1 |
0.0027 |
| 3 |
ALLERGY TEST POSITIVE |
1 |
0.0022 |
| 4 |
INJECTION SITE RECALL REACTION |
1 |
0.0020 |
| 5 |
MUSCLE ABSCESS |
1 |
0.0016 |
| 6 |
FIBROCYSTIC BREAST DISEASE |
1 |
0.0014 |
| 7 |
ORGASM ABNORMAL |
1 |
0.0012 |
| 8 |
LIP PRURITUS |
1 |
0.0012 |
| 9 |
ADENOMA BENIGN |
1 |
0.0012 |
| 10 |
PRODUCT COATING ISSUE |
1 |
0.0010 |
| 11 |
ALLERGY TO ANIMAL |
1 |
0.0009 |
| 12 |
LARYNGEAL CANCER |
1 |
0.0009 |
| 13 |
PRODUCT PACKAGE ASSOCIATED INJURY |
2 |
0.0009 |
| 14 |
PHYSICAL PRODUCT LABEL ISSUE |
1 |
0.0008 |
| 15 |
PRODUCT USED FOR UNKNOWN INDICATION |
1 |
0.0008 |
| 16 |
DRUG EFFECTIVE FOR UNAPPROVED INDICATION |
23 |
0.0008 |
| 17 |
POOR QUALITY DRUG ADMINISTERED |
4 |
0.0006 |
| 18 |
NASAL OEDEMA |
1 |
0.0006 |
| 19 |
HOMICIDE |
1 |
0.0005 |
| 20 |
PANCREATIC CYST |
1 |
0.0005 |
| 21 |
ALCOHOL INTERACTION |
1 |
0.0005 |
| 22 |
REACTION TO EXCIPIENT |
1 |
0.0004 |
| 23 |
PRODUCT PACKAGING ISSUE |
4 |
0.0004 |
| 24 |
BLOOD IMMUNOGLOBULIN E INCREASED |
1 |
0.0004 |
| 25 |
DRUG EFFECT INCOMPLETE |
13 |
0.0004 |
| 26 |
PRE-EXISTING CONDITION IMPROVED |
2 |
0.0003 |
| 27 |
CAROTID ARTERY STENOSIS |
1 |
0.0003 |
| 28 |
HANGOVER |
1 |
0.0003 |
| 29 |
AMYLASE INCREASED |
1 |
0.0003 |
| 30 |
PARANASAL SINUS DISCOMFORT |
1 |
0.0003 |
| 31 |
DEVICE OPERATIONAL ISSUE |
1 |
0.0002 |
| 32 |
CHAPPED LIPS |
1 |
0.0002 |
| 33 |
DRUG EFFECT DELAYED |
1 |
0.0002 |
| 34 |
FEELING JITTERY |
4 |
0.0002 |
| 35 |
HEPATIC ENZYME ABNORMAL |
1 |
0.0002 |
| 36 |
INTRACRANIAL PRESSURE INCREASED |
1 |
0.0002 |
| 37 |
HEART RATE ABNORMAL |
1 |
0.0002 |
| 38 |
THERAPEUTIC RESPONSE UNEXPECTED |
8 |
0.0002 |
| 39 |
ENERGY INCREASED |
1 |
0.0002 |
| 40 |
MENISCUS INJURY |
1 |
0.0002 |
| 41 |
NASAL DRYNESS |
1 |
0.0002 |
| 42 |
PRODUCT PHYSICAL ISSUE |
3 |
0.0001 |
| 43 |
GENERAL PHYSICAL CONDITION ABNORMAL |
1 |
0.0001 |
| 44 |
PAPULE |
1 |
0.0001 |
| 45 |
DRUG EFFECT LESS THAN EXPECTED |
2 |
0.0001 |
| 46 |
LIPASE INCREASED |
1 |
0.0001 |
| 47 |
RENAL CYST |
1 |
0.0001 |
| 48 |
FRUSTRATION TOLERANCE DECREASED |
1 |
0.0001 |
| 49 |
HYPERAESTHESIA |
1 |
0.0001 |
| 50 |
UPPER-AIRWAY COUGH SYNDROME |
1 |
0.0001 |
| 51 |
PRODUCT USE IN UNAPPROVED INDICATION |
30 |
0.0001 |
| 52 |
EXPIRED PRODUCT ADMINISTERED |
4 |
0.0001 |
| 53 |
EMPHYSEMA |
1 |
0.0001 |
| 54 |
DRY THROAT |
1 |
0.0001 |
| 55 |
SLUGGISHNESS |
1 |
0.0001 |
| 56 |
RENAL PAIN |
1 |
0.0001 |
| 57 |
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION |
5 |
0.0001 |
| 58 |
OCULAR DISCOMFORT |
1 |
0.0001 |
| 59 |
REBOUND EFFECT |
1 |
0.0001 |
| 60 |
GASTRIC HAEMORRHAGE |
1 |
0.0001 |
| 61 |
ACCIDENT |
1 |
0.0001 |
| 62 |
HYPERLIPIDAEMIA |
1 |
0.0001 |
| 63 |
TENDON RUPTURE |
1 |
0.0001 |
| 64 |
EYE SWELLING |
3 |
0.0001 |
| 65 |
INJECTION SITE INDURATION |
1 |
0.0001 |
| 66 |
SINUS CONGESTION |
1 |
0.0001 |
| 67 |
PRODUCT TASTE ABNORMAL |
1 |
0.0001 |
| 68 |
SEASONAL ALLERGY |
1 |
0.0001 |
| 69 |
THERAPEUTIC PRODUCT EFFECT INCOMPLETE |
5 |
0.0001 |
| 70 |
DEVICE FAILURE |
1 |
0.0001 |
| 71 |
PRODUCT USE COMPLAINT |
1 |
0.0001 |
| 72 |
OBESITY |
1 |
0.0001 |
| 73 |
LIP SWELLING |
2 |
0.0001 |
| 74 |
DRUG INEFFECTIVE |
79 |
0.0001 |
| 75 |
COLD SWEAT |
1 |
0.0001 |
| 76 |
HEAD DISCOMFORT |
1 |
0.0001 |
| 77 |
DIABETES MELLITUS INADEQUATE CONTROL |
1 |
0.0001 |
| 78 |
DRUG EFFECT DECREASED |
3 |
0.0001 |
| 79 |
HAEMATOCHEZIA |
3 |
0.0001 |
| 80 |
GASTRIC ULCER |
1 |
0.0001 |
| 81 |
INJECTION SITE WARMTH |
1 |
0.0000 |
| 82 |
POOR QUALITY SLEEP |
1 |
0.0000 |
| 83 |
RHINORRHOEA |
3 |
0.0000 |
| 84 |
PRURITUS GENERALISED |
1 |
0.0000 |
| 85 |
SOMNOLENCE |
9 |
0.0000 |
| 86 |
SNEEZING |
1 |
0.0000 |
| 87 |
PANCREATITIS ACUTE |
1 |
0.0000 |
| 88 |
ABASIA |
1 |
0.0000 |
| 89 |
HEART RATE INCREASED |
4 |
0.0000 |
| 90 |
RASH GENERALISED |
1 |
0.0000 |
| 91 |
DIPLOPIA |
1 |
0.0000 |
| 92 |
GASTRITIS |
1 |
0.0000 |
| 93 |
EAR INFECTION |
1 |
0.0000 |
| 94 |
LIMB INJURY |
1 |
0.0000 |
| 95 |
HYPERSOMNIA |
1 |
0.0000 |
| 96 |
INTENTIONAL PRODUCT MISUSE |
3 |
0.0000 |
| 97 |
DYSSTASIA |
1 |
0.0000 |
| 98 |
NASAL CONGESTION |
2 |
0.0000 |
| 99 |
HEPATIC FAILURE |
1 |
0.0000 |
| 100 |
GYNAECOMASTIA |
1 |
0.0000 |
| 101 |
SWOLLEN TONGUE |
1 |
0.0000 |
| 102 |
INSOMNIA |
8 |
0.0000 |
| 103 |
URTICARIA |
5 |
0.0000 |
| 104 |
EYE PRURITUS |
1 |
0.0000 |
| 105 |
NIGHTMARE |
1 |
0.0000 |
| 106 |
PANIC ATTACK |
1 |
0.0000 |
| 107 |
RESTLESSNESS |
1 |
0.0000 |
| 108 |
DYSURIA |
1 |
0.0000 |
| 109 |
DYSGEUSIA |
2 |
0.0000 |
| 110 |
HALLUCINATION |
2 |
0.0000 |
| 111 |
PALPITATIONS |
3 |
0.0000 |
| 112 |
ABNORMAL BEHAVIOUR |
1 |
0.0000 |
| 113 |
DISORIENTATION |
1 |
0.0000 |
| 114 |
FEELING ABNORMAL |
6 |
0.0000 |
| 115 |
EXTRA DOSE ADMINISTERED |
1 |
0.0000 |
| 116 |
DYSKINESIA |
1 |
0.0000 |
| 117 |
POLLAKIURIA |
1 |
0.0000 |
| 118 |
MENTAL DISORDER |
1 |
0.0000 |
| 119 |
THERAPEUTIC PRODUCT EFFECT DECREASED |
1 |
0.0000 |
| 120 |
SKIN DISCOLOURATION |
1 |
0.0000 |
| 121 |
UPPER RESPIRATORY TRACT INFECTION |
1 |
0.0000 |
| 122 |
HYPERSENSITIVITY |
4 |
0.0000 |
| 123 |
OCULAR HYPERAEMIA |
1 |
0.0000 |
| 124 |
DIZZINESS |
10 |
0.0000 |
| 125 |
SINUSITIS |
2 |
0.0000 |
| 126 |
INFLAMMATION |
1 |
0.0000 |
| 127 |
NERVOUSNESS |
1 |
0.0000 |
| 128 |
DERMATITIS ATOPIC |
1 |
0.0000 |
| 129 |
DEPRESSED MOOD |
1 |
0.0000 |
| 130 |
CONFUSIONAL STATE |
3 |
0.0000 |
| 131 |
RASH PRURITIC |
1 |
0.0000 |
| 132 |
PRODUCT SUBSTITUTION ISSUE |
1 |
0.0000 |
| 133 |
VERTIGO |
1 |
0.0000 |
| 134 |
DISCOMFORT |
1 |
0.0000 |
| 135 |
ALANINE AMINOTRANSFERASE INCREASED |
1 |
0.0000 |
| 136 |
NEOPLASM MALIGNANT |
1 |
0.0000 |
| 137 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
3 |
0.0000 |
| 138 |
COUGH |
4 |
0.0000 |
| 139 |
SLEEP DISORDER |
1 |
0.0000 |
| 140 |
THERAPY INTERRUPTED |
1 |
0.0000 |
| 141 |
MOBILITY DECREASED |
1 |
0.0000 |
| 142 |
UNDERDOSE |
1 |
0.0000 |
| 143 |
BRONCHITIS |
1 |
0.0000 |
| 144 |
HOT FLUSH |
1 |
0.0000 |
| 145 |
CONDITION AGGRAVATED |
4 |
0.0000 |
| 146 |
BLOOD PRESSURE INCREASED |
2 |
0.0000 |
| 147 |
HEADACHE |
8 |
0.0000 |
| 148 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
0.0000 |
| 149 |
DRY MOUTH |
1 |
0.0000 |
| 150 |
TREMOR |
2 |
0.0000 |
| 151 |
ABDOMINAL DISCOMFORT |
2 |
0.0000 |
| 152 |
PRODUCT STORAGE ERROR |
1 |
0.0000 |
| 153 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
2 |
0.0000 |
| 154 |
NO ADVERSE EVENT |
2 |
0.0000 |
| 155 |
OROPHARYNGEAL PAIN |
1 |
0.0000 |
| 156 |
CHEST PAIN |
2 |
0.0000 |
| 157 |
SWELLING |
1 |
0.0000 |
| 158 |
ANXIETY |
3 |
0.0000 |
| 159 |
DRUG INTOLERANCE |
1 |
0.0000 |
| 160 |
DYSPEPSIA |
1 |
0.0000 |
| 161 |
FLUSHING |
1 |
0.0000 |
| 162 |
CHEST DISCOMFORT |
1 |
0.0000 |
| 163 |
ABDOMINAL PAIN UPPER |
2 |
0.0000 |
| 164 |
HYPERTENSION |
2 |
0.0000 |
| 165 |
INFLUENZA |
1 |
0.0000 |
| 166 |
NAUSEA |
7 |
0.0000 |
| 167 |
DEPRESSION |
2 |
0.0000 |
| 168 |
INCORRECT DOSE ADMINISTERED |
2 |
0.0000 |
| 169 |
OEDEMA PERIPHERAL |
1 |
0.0000 |
| 170 |
VISUAL IMPAIRMENT |
1 |
0.0000 |
| 171 |
INJECTION SITE ERYTHEMA |
1 |
0.0000 |
| 172 |
DYSPNOEA |
4 |
0.0000 |
| 173 |
PAIN IN EXTREMITY |
2 |
0.0000 |
| 174 |
PERIPHERAL SWELLING |
1 |
0.0000 |
| 175 |
TOXICITY TO VARIOUS AGENTS |
1 |
0.0000 |
| 176 |
MUSCLE SPASMS |
1 |
0.0000 |
| 177 |
NASOPHARYNGITIS |
1 |
0.0000 |
| 178 |
PRODUCT USE ISSUE |
1 |
0.0000 |
| 179 |
BLOOD GLUCOSE INCREASED |
1 |
0.0000 |
| 180 |
FATIGUE |
4 |
0.0000 |
| 181 |
ERYTHEMA |
1 |
0.0000 |
| 182 |
ARTHRALGIA |
2 |
0.0000 |
| 183 |
DIARRHOEA |
3 |
0.0000 |
| 184 |
CONSTIPATION |
1 |
0.0000 |
| 185 |
WEIGHT DECREASED |
1 |
0.0000 |
| 186 |
PAIN |
2 |
0.0000 |
| 187 |
PNEUMONIA |
1 |
0.0000 |
| 188 |
ASTHENIA |
1 |
0.0000 |
| 189 |
PRURITUS |
1 |
0.0000 |
| 190 |
RASH |
1 |
0.0000 |
| 191 |
MALAISE |
1 |
0.0000 |
| 192 |
VOMITING |
1 |
0.0000 |
| 193 |
DEATH |
1 |
0.0000 |